Athersys Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



Athersys to Host First Quarter Financial Results Call

CLEVELAND, Apr 29, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its first quarter financial results at approximately 4:00 p.m. Eastern Time (ET) on Thursday, May 6, 2010, and host a conference call shortly thereafter at 4:30 p.m. ET to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call.

Investors and other interested parties are invited to listen to the conference call by dialing 800-273-1254 in the U.S. and Canada, 973-638-3440 from abroad, or via a live Internet broadcast at the Company's website at www.athersys.com under the Investors section.

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 p.m. (Eastern Time) on May 20, 2010, at the aforementioned URL, or by dialing 800-642-1687 in the U.S. and Canada, or 706-645-9291 from abroad, and entering access code 72749402.

About Athersys

Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem(R), a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE(R)). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.

The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Athersys, Inc.

CONTACT:  Athersys, Inc.
William (B.J.) Lehmann, J.D., President and
Chief Operating Officer
(216) 431-9900
bjlehmann@athersys.com
In-Site Communications
Investor Relations:
Lisa M. Wilson
(917) 543-9932
lwilson@insitecony.com
Pure Communications, Inc.
Media Relations:
Dan Budwick
(973) 271-6085
dan@purecommunicationsinc.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX

Close window | Back to top